Together, these data indicate a CD8-dependent anti-PD-1 response in mice with 4MOSC1 tumors, but with limited durable disease control or tumor regression, which is similar to the clinical response to anti-PD-1 therapies in HNSCC patients14,16. Here, CD8A is linked to neoplasm.